The biotechnology major and pharmaceutical company Mylan N V announced the launch of their insulin biosimilar Semglee.

Biocon and Mylan have been working for a decade on a biosimilar version of the drug, originally sold by Amgen under brand name Enbrel.

Fulphila is expected to contribute to Biocon’s revenue in FY19, as well as to its profits through a profitshare arrangement with Mylan.

Firms have been asked to share details about a change in the manufacturing site for glargine from Bengaluru to a new facility in Malaysia.

Ogivri is the first USFDA approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the...

The company said it does not expect the CRL to impact the timing of the launch of biosimilar Pegfilgrastim in the US market.

The USFDA's Oncology Drugs Advisory Committee voted 16-0 in support of the eligible indications of the original product.

The proposed biosimilar Pegfilgrastim is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the ...

“This is the second BLA accepted for review by FDA as part of the Mylan and Biocon partnership within the past two months”, said Rajiv Mali...

Biocon said that the FDA's acceptance for review of this biosimilar is an outcome of the company’s strong R&D and manufacturing capabilitie...

This is Mylan and Biocon's "first US regulatory submission through the 351(k) pathway and reinforces the strength of collaboration."

Mylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.

Mylan and Biocon, who co-developed the proposed biosimilar, received EMA's acceptance of the submission for review, Biocon said in a statem...

Bangalore-based Biocon and US generic drugmaker Mylan have challenged Delhi High Court’s interim order which barred them from using Roche’s...

Biocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.

Biocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.

In 2009, Mylan and Biocon had come together to develop five blockbuster biologic drugs in cancer and pain areas.